Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Completed 6Withdrawn 3Terminated 2Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 4Neoplasms 3Multiple Myeloma 3Sarcoma 2Neoplasms, Plasma Cell 2Fatigue 1Desmoplastic Small Round Cell Tumor 1Carcinoma 1Breast Neoplasms 1Bone Neoplasms 1Adenocarcinoma 1

Interventions

Cisplatin 9pembrolizumab 7Radiosurgery 6Gemcitabine 6Paclitaxel 5Dexamethasone 5Taxes 4Carboplatin 4trametinib 3ibrutinib 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Nivolumab 3Magnetic Resonance Spectroscopy 3Lenalidomide 3Fluorouracil 3Erlotinib Hydrochloride 3Blood Specimen Collection 3Ascorbic Acid 3venetoclax 2veliparib 2tocilizumab 2pazopanib 2obinutuzumab 2naquotinib 2lenvatinib 2fludarabine 2enzalutamide 2Vemurafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Neoplasms × Ascorbic Acid × Clear all
NCT03697239 2019-06-11

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

University of California, San Diego

Phase 1/2 Withdrawn
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03797443 2019-05-31

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Piedmont Cancer Institute

Phase 1/2 Withdrawn
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

NCT03908333 2019-05-30

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Medical College of Wisconsin

Phase 1/2 Withdrawn
Gastrointestinal

Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡